LOGIN  |  REGISTER
Terns Pharmaceuticals
Recursion

Bionano Genomics Presented at H.C. Wainwright Global Life Sciences Conference

March 10, 2021 | Last Trade: US$1.90 0.09 -4.52

Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management presented virtually at the H.C. Wainwright Global Life Sciences Conference, which took place March 9-10, 2021. The presentation by Bionano CEO Dr. Erik Holmlin is available on-demand through the H.C. Wainwright conference portal and the Events page in the Investors section of Bionano’s website at https://ir.bionanogenomics.com/. It will be archived on Bionano’s website for 30 days following the event.

About Bionano Genomics

Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 430-7577
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media Contact:
Darren Opland, PhD
LifeSci Communications
+1 (617) 733-7668
This email address is being protected from spambots. You need JavaScript enabled to view it.


Assertio

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page